europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

Chemically Synthesized Proteins Referencing Biological Medicinal Products

29/06/2018
POSITION PAPER
Chemically Synthesized Proteins Referencing Biological Medicinal Products

Chemically Synthesized Proteins Referencing Biological Medicinal Products (Synthetic Peptides)

Executive summary

The current situation

Some proteins can be produced either by using a biological manufacturing process or through chemical synthesis. After loss of exclusivity follow-on products could use one of the two manufacturing principles and, in EU, both chemically synthesized and biologically produced follow-ons are allowed to reference a biological originator.

EMA classifies a follow-on product as a small molecule or as a biological medicinal product1 based on its own manufacturing process, rather than that of its reference product. This classification determines the available legal basis to be used for registration. Thus, today follow-ons produced by different methods will be classified differently, as biosimilars, hybrids or generics, even though they all reference the same biological original, and all are present on the entire, or parts of the EU market, simultaneously.

The problem

Follow-on products that have been classified differently have differing requirements for documentation, prescribing, dispensing and adverse event reporting despite referencing the same product and despite being present on the EU market simultaneously. To address this, we suggest that all follow-on products to biological medicinal products be treated in a consistent manner following biosimilar principles for the review and registration in EU.

EuropaBio call for action

EuropaBio would welcome a dialogue with the European stakeholders on the best way of ensuring equal and transparent measures for assessment, traceability, adverse event reporting, prescribing and dispensing for all follow-ons of a biologic originator. EuropaBio would also welcome a guideline for chemically synthesized proteins.

Download the file below to read the full Position Paper.

Chemically Synthesized Proteins Referencing Biological Medicinal Products (Synthetic Peptides)


Download
2018_06_H_WP_White-Paper-Synthetic-PeptidesDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
01/02/2023

Joint Statement: The Data Act is a leap into the unknown


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies